Efecto del compuesto correlacionado de hexosa activo (AHCC) en patologías inflamatorias intestinalestriquinosis y enfermedad inflamatoria intestinal (EII)

  1. López Cauce, Beatriz
Dirixida por:
  1. Juan José García Rodríguez Director
  2. Marta Puerto Cantero Director
  3. Luis Alberto Menchén Viso Director

Universidade de defensa: Universidad Complutense de Madrid

Fecha de defensa: 04 de xuño de 2021

Tribunal:
  1. Eduardo Martínez Naves Presidente
  2. Alicia Gómez Barrio Secretaria
  3. José Antonio Pajares Díaz Vogal
  4. Rosa Maria Del Campo Moreno Vogal
  5. Manuel Barreiro de Acosta Vogal
Departamento:
  1. Medicina

Tipo: Tese

Teseo: 155649 DIALNET lock_openDocta Complutense editor

Resumo

AHCC is a natural product discovered in 1986 and patented by the Japanese company Amino up, which is obtained from the fermentation of the mycelium of the L. edodes fungus. It is described as a nutraceutical or an immunomodulator due to its ability to modulate the immune response to challenges of different etiology (1). Currently, it is used as concomitant treatment in cancer patients, since it reduces the generalized effects of chemotherapy (2-5).In the present work, we wanted to test the effects of AHCC in an organ where the regulation of the immune system is fundamental: the intestine. To do this, several models were used: the murine model of trichinosis and models of inflammatory bowel disease (IBD), both acute and chronic (6, 7)...